Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 170

1.

Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors.

Fan QW, Weiss WA.

Methods Mol Biol. 2012;821:349-59. doi: 10.1007/978-1-61779-430-8_22.

PMID:
22125077
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.

Gulati N, Karsy M, Albert L, Murali R, Jhanwar-Uniyal M.

Int J Oncol. 2009 Oct;35(4):731-40.

PMID:
19724909
[PubMed - indexed for MEDLINE]
3.

Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.

Xing WJ, Zou Y, Han QL, Dong YC, Deng ZL, Lv XH, Jiang T, Ren H.

Clin Exp Pharmacol Physiol. 2013 Jan;40(1):13-21. doi: 10.1111/1440-1681.12026.

PMID:
23110505
[PubMed - indexed for MEDLINE]
4.

Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.

Chiarini F, FalĂ  F, Tazzari PL, Ricci F, Astolfi A, Pession A, Pagliaro P, McCubrey JA, Martelli AM.

Cancer Res. 2009 Apr 15;69(8):3520-8. doi: 10.1158/0008-5472.CAN-08-4884. Epub 2009 Apr 7.

PMID:
19351820
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.

Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM.

PLoS Biol. 2009 Feb 10;7(2):e38. doi: 10.1371/journal.pbio.1000038.

PMID:
19209957
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.

Breuleux M, Klopfenstein M, Stephan C, Doughty CA, Barys L, Maira SM, Kwiatkowski D, Lane HA.

Mol Cancer Ther. 2009 Apr;8(4):742-53. doi: 10.1158/1535-7163.MCT-08-0668.

PMID:
19372546
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.

Zou CY, Smith KD, Zhu QS, Liu J, McCutcheon IE, Slopis JM, Meric-Bernstam F, Peng Z, Bornmann WG, Mills GB, Lazar AJ, Pollock RE, Lev D.

Mol Cancer Ther. 2009 May;8(5):1157-68. doi: 10.1158/1535-7163.MCT-08-1008. Epub 2009 May 5.

PMID:
19417153
[PubMed - indexed for MEDLINE]
Free Article
8.

Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.

Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B, Kim J, Verheijen J, Curran K, Malwitz DJ, Cole DC, Ellingboe J, Ayral-Kaloustian S, Mansour TS, Gibbons JJ, Abraham RT, Nowak P, Zask A.

Cancer Res. 2009 Aug 1;69(15):6232-40. doi: 10.1158/0008-5472.CAN-09-0299. Epub 2009 Jul 7.

PMID:
19584280
[PubMed - indexed for MEDLINE]
Free Article
9.

Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.

Wang X, Yue P, Kim YA, Fu H, Khuri FR, Sun SY.

Cancer Res. 2008 Sep 15;68(18):7409-18. doi: 10.1158/0008-5472.CAN-08-1522.

PMID:
18794129
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.

Badura S, Tesanovic T, Pfeifer H, Wystub S, Nijmeijer BA, Liebermann M, Falkenburg JH, Ruthardt M, Ottmann OG.

PLoS One. 2013 Nov 14;8(11):e80070. doi: 10.1371/journal.pone.0080070. eCollection 2013.

PMID:
24244612
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, Claret FX, Rassidakis GZ.

Cancer Res. 2006 Jul 1;66(13):6589-97.

PMID:
16818631
[PubMed - indexed for MEDLINE]
Free Article
12.

Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates.

Mazzoletti M, Bortolin F, Brunelli L, Pastorelli R, Di Giandomenico S, Erba E, Ubezio P, Broggini M.

Cancer Res. 2011 Jul 1;71(13):4573-84. doi: 10.1158/0008-5472.CAN-10-4322. Epub 2011 May 20.

PMID:
21602434
[PubMed - indexed for MEDLINE]
Free Article
13.

Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo.

Werzowa J, Koehrer S, Strommer S, Cejka D, Fuereder T, Zebedin E, Wacheck V.

J Invest Dermatol. 2011 Feb;131(2):495-503. doi: 10.1038/jid.2010.327. Epub 2010 Nov 4.

PMID:
21048785
[PubMed - indexed for MEDLINE]
Free Article
14.

Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma.

Venkatesh HS, Chaumeil MM, Ward CS, Haas-Kogan DA, James CD, Ronen SM.

Neuro Oncol. 2012 Mar;14(3):315-25. doi: 10.1093/neuonc/nor209. Epub 2011 Dec 12.

PMID:
22156546
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells.

Chen G, Chen SM, Wang X, Ding XF, Ding J, Meng LH.

J Biol Chem. 2012 Apr 6;287(15):12132-41. doi: 10.1074/jbc.M111.302299. Epub 2012 Feb 15. Erratum in: J Biol Chem. 2012 Jun 1;287(23):19336.

PMID:
22337890
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Akt and autophagy cooperate to promote survival of drug-resistant glioma.

Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, Nicolaides T, Haas-Kogan D, James CD, Oakes SA, Debnath J, Shokat KM, Weiss WA.

Sci Signal. 2010 Nov 9;3(147):ra81. doi: 10.1126/scisignal.2001017.

PMID:
21062993
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

EGFR signals to mTOR through PKC and independently of Akt in glioma.

Fan QW, Cheng C, Knight ZA, Haas-Kogan D, Stokoe D, James CD, McCormick F, Shokat KM, Weiss WA.

Sci Signal. 2009 Jan 27;2(55):ra4. doi: 10.1126/scisignal.2000014. Erratum in: Sci Signal. 2009;2(60):er4.

PMID:
19176518
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.

Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A, Pannetier M, Willems L, Park S, Macone A, Maira SM, Ifrah N, Dreyfus F, Herault O, Lacombe C, Mayeux P, Bouscary D.

Clin Cancer Res. 2010 Nov 15;16(22):5424-35. doi: 10.1158/1078-0432.CCR-10-1102. Epub 2010 Sep 30.

PMID:
20884625
[PubMed - indexed for MEDLINE]
Free Article
19.

Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics.

Spender LC, Inman GJ.

Mol Cancer Res. 2012 Mar;10(3):347-59. doi: 10.1158/1541-7786.MCR-11-0394. Epub 2012 Jan 12.

PMID:
22241218
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.

Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Evers BM.

J Surg Res. 2012 Aug;176(2):542-8. doi: 10.1016/j.jss.2011.10.045. Epub 2011 Nov 21.

PMID:
22261591
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk